Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1993 Sep;46(9):840–845. doi: 10.1136/jcp.46.9.840

Use of recombinant human parvovirus B19 antigens in serological assays.

H A Cubie 1, E E Leslie 1, S Smith 1, H J O'Neill 1, H Hart 1, B J Cohen 1, J M Inglis 1
PMCID: PMC501521  PMID: 8227436

Abstract

AIMS--To compare the sensitivity, specificity, and practicality of recombinant proteins in serological tests for the detection of human parvovirus B19 IgG and IgM. METHODS--Indirect enzyme linked immunosorbent assays using B19 structural proteins expressed in Escherichia coli were developed for the detection of B19 specific IgG and IgM (rELISA-G and rELISA-M). Cells infected with baculovirus expressing B19 structural proteins were also used in an indirect immunofluorescence assay for IgG and IgM antibodies (IFA-G and IFA-M). Antibody capture radioimmunoassays for IgG and IgM (GACRIA and MACRIA) were used as comparative assays. RESULTS--Twenty nine pools of intravenous immunoglobulin were clearly positive for B19 IgG by rELISA-G and contained low IgG titres by GACRIA. From 113 samples tested by all methods, sensitivities of 92% (77/84) and 97% (68/70) were obtained for ELISA and immunofluorescence, respectively, when compared with GACRIA. One hundred and sixteen samples from patients presenting with rash or arthralgia were compared by MACRIA, rELISA-M, and IFA-M. Sensitivities of both recombinant tests were more than 95%. Despite pretreatment to remove IgG or rheumatoid factor, false positive results were a problem in the rELISA-M but were not seen with the IFA-M. CONCLUSIONS--The limited supply of native antigen has severely restricted the wide application of serology for parvovirus B19. The use of recombinant antigens permitted the introduction of local screening tests which had many advantages, including quicker results and relief of the burden on the Reference Laboratory. The use of rELISA-M for sensitivity and IFA-M for specificity and confirmation proved a useful and practical combination for diagnosis of recent infection with B19, and rELISA-G allowed the immune response to be determined in selected populations.

Full text

PDF
840

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson L. J., Tsou C., Parker R. A., Chorba T. L., Wulff H., Tattersall P., Mortimer P. P. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol. 1986 Oct;24(4):522–526. doi: 10.1128/jcm.24.4.522-526.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brown C. S., van Bussel M. J., Wassenaar A. L., van Elsacker-Niele A. M., Weiland H. T., Salimans M. M. An immunofluorescence assay for the detection of parvovirus B19 IgG and IgM antibodies based on recombinant viral antigen. J Virol Methods. 1990 Jul;29(1):53–62. doi: 10.1016/0166-0934(90)90007-3. [DOI] [PubMed] [Google Scholar]
  3. Brown T., Anand A., Ritchie L. D., Clewley J. P., Reid T. M. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet. 1984 Nov 3;2(8410):1033–1034. doi: 10.1016/s0140-6736(84)91126-7. [DOI] [PubMed] [Google Scholar]
  4. Cohen B. J., Brown K. E. Laboratory infection with human parvovirus B19. J Infect. 1992 Jan;24(1):113–114. doi: 10.1016/0163-4453(92)91374-k. [DOI] [PubMed] [Google Scholar]
  5. Cohen B. J., Mortimer P. P., Pereira M. S. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J Hyg (Lond) 1983 Aug;91(1):113–130. doi: 10.1017/s0022172400060095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Erdman D. D., Usher M. J., Tsou C., Caul E. O., Gary G. W., Kajigaya S., Young N. S., Anderson L. J. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol. 1991 Oct;35(2):110–115. doi: 10.1002/jmv.1890350207. [DOI] [PubMed] [Google Scholar]
  7. Frickhofen N., Abkowitz J. L., Safford M., Berry J. M., Antunez-de-Mayolo J., Astrow A., Cohen R., Halperin I., King L., Mintzer D. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990 Dec 15;113(12):926–933. doi: 10.7326/0003-4819-113-12-926. [DOI] [PubMed] [Google Scholar]
  8. Gerrits C. A West African epilepsy focus. Lancet. 1983 Feb 12;1(8320):358–358. doi: 10.1016/s0140-6736(83)91663-x. [DOI] [PubMed] [Google Scholar]
  9. Kajigaya S., Shimada T., Fujita S., Young N. S. A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7601–7605. doi: 10.1073/pnas.86.19.7601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kurtz J. B., Anderson M. J. Cross-reactions in rubella and parvovirus specific IgM tests. Lancet. 1985 Dec 14;2(8468):1356–1356. doi: 10.1016/s0140-6736(85)92647-9. [DOI] [PubMed] [Google Scholar]
  11. Kurtzman G. J., Ozawa K., Cohen B., Hanson G., Oseas R., Young N. S. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med. 1987 Jul 30;317(5):287–294. doi: 10.1056/NEJM198707303170506. [DOI] [PubMed] [Google Scholar]
  12. Morinet F., Courouce A. M., Galibert F., Perol Y. The use of labeled fusion protein for detection of B19 parvovirus IgM antibodies by an immunocapture test. J Virol Methods. 1991 Apr;32(1):21–30. doi: 10.1016/0166-0934(91)90181-x. [DOI] [PubMed] [Google Scholar]
  13. O'Neill H. J., Coyle P. V. Two anti-parvovirus B 19 IgM capture assays incorporating a mouse monoclonal antibody specific for B 19 viral capsid proteins VP 1 and VP 2. Arch Virol. 1992;123(1-2):125–134. doi: 10.1007/BF01317143. [DOI] [PubMed] [Google Scholar]
  14. Patou G., Ayliffe U. Evaluation of commercial enzyme linked immunosorbent assay for detection of B19 parvovirus IgM and IgG. J Clin Pathol. 1991 Oct;44(10):831–834. doi: 10.1136/jcp.44.10.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pattison J. R., Jones S. E., Hodgson J., Davis L. R., White J. M., Stroud C. E., Murtaza L. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet. 1981 Mar 21;1(8221):664–665. doi: 10.1016/s0140-6736(81)91579-8. [DOI] [PubMed] [Google Scholar]
  16. Pillay D., Patou G., Hurt S., Kibbler C. C., Griffiths P. D. Parvovirus B19 outbreak in a children's ward. Lancet. 1992 Jan 11;339(8785):107–109. doi: 10.1016/0140-6736(92)91009-w. [DOI] [PubMed] [Google Scholar]
  17. Reid K. G., Cuthbertson B., Jones A. D., McIntosh R. V. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products. Vox Sang. 1988;55(2):75–80. doi: 10.1111/j.1423-0410.1988.tb05140.x. [DOI] [PubMed] [Google Scholar]
  18. Schwarz T. F., Roggendorf M., Deinhardt F. Human parvovirus B19: ELISA and immunoblot assays. J Virol Methods. 1988 Jun;20(2):155–168. doi: 10.1016/0166-0934(88)90149-8. [DOI] [PubMed] [Google Scholar]
  19. Shiraishi H., Sasaki T., Nakamura M., Yaegashi N., Sugamura K. Laboratory infection with human parvovirus B19. J Infect. 1991 May;22(3):308–310. doi: 10.1016/s0163-4453(05)80026-x. [DOI] [PubMed] [Google Scholar]
  20. Söderlund M., Brown K. E., Meurman O., Hedman K. Prokaryotic expression of a VP1 polypeptide antigen for diagnosis by a human parvovirus B19 antibody enzyme immunoassay. J Clin Microbiol. 1992 Feb;30(2):305–311. doi: 10.1128/jcm.30.2.305-311.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES